2222344-98-9 (ORIC-101,ORIC-101)

(8S,9R,10S,11R,13R,14R,17R)-17-(3,3-Dimethylbut-1-ynyl)-17-hydroxy-13-methyl-11-[4-[methyl(propan-2-;ORIC-101;(8R,9S,10R,11S,13S,14S,17S)-17-(3,3-dimethylbut-1-ynyl)-17-hydroxy-13-methyl-11-(4-(methyl(propan-2-yl)amino)phenyl)-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta(a)phenanthren-3-one;SCHEMBL20048238;BDBM50368933;Glucocorticoid Receptor Antagonist ORIC-101;G16694;EX-A8589;GTPL13167;VI6E2D3CYP;UNII-VI6E2D3CYP;MS-29320;DA-76459;CHEMBL4161754;compound 28 [PMID: 30091920];CS-0062840;ORIC-101?;19,21-Dinorchol-4-en-20(22)-yn-3-one, 17-hydroxy-23,23-dimethyl-11-(4-(methyl(1-methylethyl)amino)phenyl)-, (11beta,17alpha)-;(8R,9S,10R,11S,13S,14S,17S)-17-(3,3-dimethylbut-1-ynyl)-17-hydroxy-13-methyl-11-[4-[methyl(propan-2-yl)amino]phenyl]-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;19,21-DINORCHOL-4-EN-20(22)-YN-3-ONE, 17-HYDROXY-23,23-DIMETHYL-11-(4-(METHYL(1-METHYLETHYL)AMINO)PHENYL)-, (11.BETA.,17.ALPHA.)-;ORIC 101 [WHO-DD];HY-112710;ORIC101;2222344-98-9;AKOS040742347;compound 28 (PMID: 30091920);GR Antagonist ORIC-101;

VNLTWJIWEYPBIF-SXJSTINISA-N

1S/C34H47NO2/c1-22(2)35(7)25-11-8-23(9-12-25)29-21-33(6)30(16-17-34(33,37)19-18-32(3,4)5)28-14-10-24-20-26(36)13-15-27(24)31(28)29/h8-9,11-12,20,22,27-31,37H,10,13-17,21H2,1-7H3/t27-,28-,29+,30-,31+,33-,34+/m1/s1

O([H])[C@]1(C#CC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@]2([H])[C@@]3([H])C([H])([H])C([H])([H])C4=C([H])C(C([H])([H])C([H])([H])[C@@]4([H])[C@]3([H])[C@]([H])(C3C([H])=C([H])C(=C([H])C=3[H])N(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[C@]21C([H])([H])[H])=O